Overview

Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease

Status:
Completed

Trial end date:
2010-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether mipomersen safely and effectively lowers low-density lipoprotein cholesterol (LDL-C) in patients with Heterozygous Familial Hypercholesterolemia (HeFH) and coronary artery disease (CAD) who are already on a stable dose of other lipid-lowering agents (including maximally tolerated statin therapy).

Phase:

Phase 3

Details

Lead Sponsor:

Kastle Therapeutics, LLC

Collaborator:

Ionis Pharmaceuticals, Inc.

Treatments:

Mipomersen